Connect with us
In phase 3 trials, Pfizer and BioNTech's vaccine showed strong immune responses against influenza A and COVID-19 but failed to meet key objectives for influenza B....
BioNTech 's turnover in 2022 was €17.31 billion, which represented a decrease of 8.8%. By business segments, those from the marketing of medicines amounted to €17.2...
Before being authorized, the vaccine developed by Hipra will have to pass stage I/II, where its safety will have to be demonstrated. Phase III will then...
If all goes well in D.C. and with the vaccine and the economy, the Fed should begin to significantly taper its QE program and support of...